RedHill Biopharma (RDHL) Tops Q2 Loss Views
RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.07), $0.39 better than the analyst estimate of ($0.46).
For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.
RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.07), $0.39 better than the analyst estimate of ($0.46).
For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.